01—Abstract
Summary
Summary of the 10-Q filed May 3, 2024. Cited figures are marked; the original filing is the authoritative source.
Thermo Fisher Scientific Inc. (TMO) reported its first-quarter 2024 financial results, showing total revenues of $10.35 billiona, a decrease of 3% compared to the prior year's $10.71 billion.
This decline was primarily driven by a decrease in Life Sciences Solutions and Analytical Instruments segments, partly offset by stable performance in Specialty Diagnostics and Laboratory Products and Biopharma Services. Despite the revenue dip, operating income saw a modest 6% increase to $1.66 billionb, leading to diluted earnings per share (EPS) of $3.46, up from $3.32 in the first quarter of 2023. The company continues to navigate a complex market, with a decrease in COVID-19 related revenue impacting performance.
However, management highlights strong productivity improvements and strategic investments as key drivers for future growth. The company also announced its intent to acquire Olink Holding AB for approximately $3.1 billionc, expected to close mid-year 2024, which is anticipated to enhance its proteomics capabilities.
02—Key points
Key Highlights
- Total revenues for Q1 2024 were $10.35 billion, a 3% decrease year-over-year, primarily due to lower demand for COVID-19 related products and challenging macroeconomic conditions.
- Operating income increased by 6% to $1.66 billion, while diluted EPS rose to $3.46 from $3.32 in the prior year's quarter, indicating improved profitability on a per-share basis.
- The Life Sciences Solutions segment experienced a 13% revenue decline, largely due to the moderation of COVID-19 related revenue and lower bioproduction activity.
- Thermo Fisher announced a proposed acquisition of Olink Holding AB for approximately $3.1 billion, aiming to expand its proteomics offerings.
- Free cash flow generation remained strong, with $908 million in the quarter, significantly up from $277 million in Q1 2023, showcasing robust cash generation capabilities.
- The company repurchased $3.0 billion of its common stock in the quarter, reflecting a continued commitment to returning capital to shareholders.
- Cash and cash equivalents decreased to $5.5 billion from $8.1 billion at the end of 2023, partly due to significant share repurchases and investments.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed May 3, 2024Financial Statements
| Revenue | $10.35B |
| R&D Expenses | $331.00M |
| SG&A Expenses | $2.18B |
| Operating Expenses | $8.68B |
| Operating Income | $1.66B |
| Interest Expense | $363.00M |
| Net Income | $1.33B |
| EPS (Basic) | $3.47 |
| EPS (Diluted) | $3.46 |
| Shares Outstanding (Basic) | 382.00M |
| Shares Outstanding (Diluted) | 384.00M |
05—Questions
Frequently Asked Questions
What drove the decrease in total revenues?
The decrease in total revenues by 3% to $10.35 billion in Q1 2024 was primarily driven by a significant moderation in COVID-19 related revenue, a decline in the Life Sciences Solutions and Analytical Instruments segments, and challenging macroeconomic conditions, particularly in China. This was partially offset by stable performance in Specialty Diagnostics and Laboratory Products and Biopharma Services.
How did the proposed acquisition of Olink Holding AB impact the financial results?
The Olink acquisition was announced on October 17, 2023, and is expected to close by mid-year 2024. As of the Q1 2024 filing, it has not yet been completed, so its financial results are not yet included in Thermo Fisher's consolidated statements. The company intends to finance the purchase price with cash on hand and debt issuance.
What is the outlook for free cash flow?
Thermo Fisher demonstrated strong free cash flow generation in Q1 2024, totaling $908 million, a substantial increase from $277 million in the prior year's quarter. The company expects this trend to continue, driven by its operational efficiency and growth strategies, providing ample resources for investments and capital allocation.
How is the company managing its debt and liquidity?
As of March 30, 2024, Thermo Fisher had $35.6 billion in total debt. The company's liquidity position remains solid, with $5.5 billion in cash and cash equivalents and a $5.0 billion revolving credit facility. Management believes its existing cash, future operating cash flow, and available borrowing capacity are sufficient to meet its cash requirements for at least the next 24 months.
06—Continue